Noa Lavi

1.3k citations
58 papers · 603 indexed · h-index 16
Topics
Multiple Myeloma Research and Treatments (27 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers)Acute Myeloid Leukemia Research (10 papers)
Partner nations
IsraelUnited StatesItaly

In The Last Decade

Noa Lavi

56 papers receiving 592 citations

Peers

Noa Lavi
Comparison fields: 5 of 79
  • Hematology 258
  • Molecular Biology 214
  • Oncology 200
  • Genetics 155
  • Epidemiology 103
Replace Minako Mori with:
Minako Mori Japan
B. Martino Italy
Rabi Hanna United States
Lucrecia Yáñez Spain
Ah Moy Tan Singapore
Hassan B. Alkhateeb United States
Elham Askari Iran
J.J. Cornelissen Netherlands
Shun-ichi Kimura Japan
Montserrat Rovira Spain
Noa Lavi relative to Minako Mori Japan Minako Mori's profile →
Citations per field
00.5×3.6×
Minako Mori · 1×
Citations per year

Countries citing papers authored by Noa Lavi

Since Specialization
Citations

This map shows the geographic impact of Noa Lavi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noa Lavi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noa Lavi more than expected).

Fields of papers citing papers by Noa Lavi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noa Lavi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noa Lavi. The network helps show where Noa Lavi may publish in the future.

Co-authorship network of co-authors of Noa Lavi

This figure shows the co-authorship network connecting the top 25 collaborators of Noa Lavi. A scholar is included among the top collaborators of Noa Lavi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noa Lavi. Noa Lavi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 3
2 16
3 1
4 2
5 2
6 12
7 1
8 13
9 30
10 10
11 10
12 7
13 2
14 1
15 15
16 7
17
At Home Under Development: A Housing Project for the Hunter-gatherers Nayaka of the Nilgiris
13
18 21
19 7
20 9

About Noa Lavi

Noa Lavi is a scholar working on Hematology, Genetics and Oncology, having authored 58 papers that have together received 603 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (27 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers) and Acute Myeloid Leukemia Research (10 papers). The work is most often cited by research in Hematology (258 citations), Genetics (155 citations) and Molecular Medicine (59 citations). Noa Lavi has collaborated with scholars based in Israel, United States and Italy. Frequent co-authors include Irit Avivi, Netanel A. Horowitz, Ilana Oren, Benjamin Brenner, Tsila Zuckerman, Martin Ellis, Yaël C. Cohen, Jacob M. Rowe, Alessandro M. Vannucchi and Noam Benyamini. Their work appears in journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026